Firibastat is a first-in-class oral antihypertensive drug that selectively and specifically inhibits the conversion of angiotensin II to angiotensin III. This inhibition is associated with decreased sympathetic nervous system activity and increased baroreflex activity, which led to the lower level of blood pressure. Recently, a phase 2b clinical trial was conducted to evaluate the effect of Firibastat on an understudied and underserved patient population mainly obese, high-risk and hypertensive racial minorities.
The results indicated that Firibastat is safe and effective in treating hypertension in obese patients. Source: MDedge Cardiology
